[Status of components in EGFR-related signal transduction as predictive markers for anti-EGFR antibody therapy in colorectal cancer treatment].
Anti-EGFR antibodies were designed to inhibit the receptor tyrosine kinase activity of EGFR by directly binding to the extracellular domain. Anti-EGFR antibodies have been approved or will be approved for use in Japan, the USA or Europe. Recently, many studies have investigated molecular markers can predict the response to anti-EGFR antibodies so as to discriminate responders and non-responders. Activating KRAS mutation has been shown to be a potent predictive marker of resistance to anti-EGFR antibodies. Moreover, BRAF mutations, PIK3CA mutations or loss of PTEN have also been shown to be other molecular markers to predict resistance to anti-EGFR antibodies. Further studies must integrate these markers into clinical decisions to use or not use anti-EGFR antibodies.
Shimodaira
Hideki
H
Institute of Development, Aging and Cancer, Tohoku University, Tohoku University Hospital, Aoba-ku, Sendai, Japan.
Soeda
Hiroshi
H
Komine
Keigo
K
Ishioka
Chikashi
C
D000906:Antibodies / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D016503:Drug Delivery Systems; D066246:ErbB Receptors / Q000276:immunology* / Q000502:physiology*; D006801:Humans; D015398:Signal Transduction
D000906:Antibodies; D066246:ErbB Receptors